NO760993L - - Google Patents

Info

Publication number
NO760993L
NO760993L NO760993A NO760993A NO760993L NO 760993 L NO760993 L NO 760993L NO 760993 A NO760993 A NO 760993A NO 760993 A NO760993 A NO 760993A NO 760993 L NO760993 L NO 760993L
Authority
NO
Norway
Prior art keywords
radical
formula
compound
alkyl
dihydro
Prior art date
Application number
NO760993A
Other languages
English (en)
Norwegian (no)
Inventor
D R Brittain
E D Brown
W Hepworth
G J Stacey
Original Assignee
Ici Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB11644/75A external-priority patent/GB1502312A/en
Application filed by Ici Ltd filed Critical Ici Ltd
Publication of NO760993L publication Critical patent/NO760993L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/24Oxygen atoms attached in position 8
    • C07D215/26Alcohols; Ethers thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NO760993A 1975-03-20 1976-03-19 NO760993L (enEXAMPLES)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB11644/75A GB1502312A (en) 1975-03-20 1975-03-20 Quinolone derivatives
GB4204375 1975-10-14

Publications (1)

Publication Number Publication Date
NO760993L true NO760993L (enEXAMPLES) 1976-09-21

Family

ID=26248416

Family Applications (1)

Application Number Title Priority Date Filing Date
NO760993A NO760993L (enEXAMPLES) 1975-03-20 1976-03-19

Country Status (19)

Country Link
US (1) US4066651A (enEXAMPLES)
JP (1) JPS51118773A (enEXAMPLES)
AU (1) AU1147676A (enEXAMPLES)
CS (1) CS188273B2 (enEXAMPLES)
DD (1) DD124117A5 (enEXAMPLES)
DE (1) DE2611824A1 (enEXAMPLES)
DK (1) DK115376A (enEXAMPLES)
ES (1) ES446234A1 (enEXAMPLES)
FI (1) FI760729A7 (enEXAMPLES)
FR (1) FR2304342A1 (enEXAMPLES)
HU (1) HU172032B (enEXAMPLES)
IE (1) IE43079B1 (enEXAMPLES)
IL (1) IL49126A0 (enEXAMPLES)
LU (1) LU74594A1 (enEXAMPLES)
NL (1) NL7602834A (enEXAMPLES)
NO (1) NO760993L (enEXAMPLES)
PT (1) PT64921B (enEXAMPLES)
SE (1) SE434394B (enEXAMPLES)
SU (1) SU648090A3 (enEXAMPLES)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
EP0382185B1 (en) * 1989-02-10 1994-06-15 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5225402A (en) * 1989-02-10 1993-07-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
DE69128481T2 (de) * 1990-09-07 1998-04-09 Schering Corp Antivirale und antihypertensive verbindungen
TW198715B (enEXAMPLES) * 1991-04-19 1993-01-21 Dtsuka Seiyaku Kk
DE69207560T2 (de) * 1991-06-07 1996-06-27 Otsuka Pharma Co Ltd Antidiabetikum
DE19839499A1 (de) * 1998-08-29 2000-03-02 Merck Patent Gmbh 2-Oxo-2H-chinolinderivate
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
CN1391576A (zh) * 1999-08-27 2003-01-15 利甘德药品公司 雄激素受体调节剂化合物及方法
JP2003508397A (ja) 1999-08-27 2003-03-04 リガンド・ファーマシューティカルズ・インコーポレイテッド アンドロゲンレセプターモジュレーターとしての8−置換−6−トリフルオロメチル−9−ピリド[3,2−g]キノリン化合物
PE20010647A1 (es) 1999-09-14 2001-06-23 Lilly Co Eli Moduladores de receptores de retinoide x (rxr) con perfil farmacologico mejorado
FR2811912B1 (fr) * 2000-07-21 2003-02-07 Gattefosse Ets Sa Procede d'enrobage de particules solides par un agent thermofusible, et particules solides ainsi enrobees
CA2536349A1 (en) * 2003-08-22 2005-03-03 Ligand Pharmaceuticals Incorporated 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI417095B (zh) * 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) * 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
DE602008004794D1 (de) * 2007-09-14 2011-03-10 Addex Pharmaceuticals Sa 1',3'-disubstituierte 4-phenyl-3,4,5,6-tetrahydro-2h,1'h-ä1,4'übipyridinyl-2'-one
EP2205565B1 (en) * 2007-09-14 2013-04-17 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
PL2200985T3 (pl) 2007-09-14 2011-12-30 Ortho Mcneil Janssen Pharmaceuticals Inc 1,3-Dipodstawione-4-(arylo-X-fenylo)-1H-pirydyn-2-ony
CA2704436C (en) * 2007-11-14 2016-01-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US20110236394A1 (en) * 2007-11-15 2011-09-29 Universite Laval Methods for the regulation of the prostaglandin f synthase (pgfs) activity of akr1b1 and uses thereof
WO2010025890A1 (en) 2008-09-02 2010-03-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
CN102232074B (zh) 2008-11-28 2014-12-03 奥梅-杨森制药有限公司 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物
AU2010246609B2 (en) 2009-05-12 2013-09-05 Addex Pharma S.A. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
AR076859A1 (es) 2009-05-12 2011-07-13 Ortho Mcneil Janssen Pharm Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos.
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
CA2815002C (en) 2010-11-08 2019-10-22 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
DK3431106T3 (da) 2014-01-21 2021-03-15 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
HUE045610T2 (hu) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3772301A (en) * 1971-11-22 1973-11-13 Warner Lambert Co (4-substituted)4-(methylsulfinyl)methylcarbostyrils

Also Published As

Publication number Publication date
FR2304342A1 (fr) 1976-10-15
SE7602339L (sv) 1976-09-21
IE43079B1 (en) 1980-12-17
ES446234A1 (es) 1977-10-01
JPS51118773A (en) 1976-10-18
FI760729A7 (enEXAMPLES) 1976-09-21
NL7602834A (nl) 1976-09-22
IE43079L (en) 1976-09-20
DD124117A5 (enEXAMPLES) 1977-02-02
DE2611824A1 (de) 1976-09-30
PT64921B (en) 1977-08-24
SE434394B (sv) 1984-07-23
SU648090A3 (ru) 1979-02-15
HU172032B (hu) 1978-05-28
CS188273B2 (en) 1979-02-28
IL49126A0 (en) 1976-05-31
PT64921A (en) 1976-04-01
LU74594A1 (enEXAMPLES) 1977-05-06
FR2304342B1 (enEXAMPLES) 1979-09-21
US4066651A (en) 1978-01-03
AU1147676A (en) 1977-09-01
DK115376A (da) 1976-09-21
DE2611824C2 (enEXAMPLES) 1987-06-19
JPH0122267B2 (enEXAMPLES) 1989-04-25

Similar Documents

Publication Publication Date Title
NO760993L (enEXAMPLES)
NO174506B (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser
NO164476B (no) Analogifremgangsmaate ved fremstilling av terapeutisk virksomme 1,2,3,5-tetrahydroimidazo-(2,1-b)-kinazoliner.
CS228536B2 (en) Production method of 3-aryl-5-isothiazole
DK162524B (da) Analogifremgangsmaade til fremstilling af 5-alkylthio-tetrazolderivater
IL42799A (en) Carbazolic history of alcohols, sites and alkanoic acids, their preparation and pharmaceutical preparations containing signal
NO881411L (no) Substituerte pyrroler.
US4755509A (en) Heterocyclic aldose reductase inhibitors and methods of using them
US4362875A (en) Process for preparing (1-acylaminomethyl)-1,2,3,4-tetrahydroisoquinolines
IE852703L (en) Oxindole antiinflammatory agents.
MX2012005189A (es) Inhibidores de ire-1-alfa.
Szmuszkovicz 3-Acylindole mannich bases and their transformation products
NO126370B (enEXAMPLES)
LT3675B (en) Indenoindole copounds ii, process for preraring them and pharmaceutical composition containing them
NO163597B (no) Styreinnretning for et ett-eller tosporet kjoeretoey.
NO142346B (no) Analogifremgangsmaate til fremstilling av nye terapeutisk aktive kondenserte n-fenylsubstituerte pyrroler
NO169648B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive arakidonsyre-derivater
US4515944A (en) 1,5-Diphenyl-2-haloalkylpyrazolin-3-one intermediates
NO803693L (no) 2,3-indoldion-derivater.
NO131930B (enEXAMPLES)
Jacobs et al. 4-Substituted Cinnoline Derivatives1
US4420476A (en) Benzofuro[3,2-c]pyrazol-3-amine derivatives
US4138490A (en) Analgesic compositions containing 1,2-dihydro-2-oxoquinol-4-ylpropionic acid derivatives
Unangst et al. 2‐Indolyl ketone synthesis
DK150158B (da) Analogifremgangsmaade til fremstilling af 4-phenylthieno-(2,3-c)piperidiner eller fysiologisk acceptable syreadditionssalte deraf